<DOC>
	<DOCNO>NCT00874120</DOCNO>
	<brief_summary>Randomized , placebo-controlled double-blind , crossover design study ; 116 subject randomize Day 1 obtain 98 complete subject . Study compose 7-day period therapy randomize active placebo treatment subsequent 6-8 day washout period , follow second 7-day period double-blind therapy agent . Ambulatory blood pressure measurement perform begin Day 7 treatment period follow administration study drug .</brief_summary>
	<brief_title>Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg Placebo ( Study CL2007-07 ) ( P07529 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<criteria>Healthy , male female volunteer must 18 year old , Body Mass Index ( BMI ) 1930 inclusive [ BMI = weight ( kilogram ) /height ( meter square ) ] . Clinical laboratory test ( complete blood count , blood chemistry , urinalysis ) , Human Immunodeficiency Virus ( HIV ) antibody , hepatitis B surface antigen , hepatitis C antibody must within normal limit clinically acceptable Investigator/Sponsor . Drug screen drug alcohol high potential abuse must negative screening . Subjects must free clinically significant disease require physician 's care and/or would interfere study evaluation , procedure participation . Subjects must agree take monoamine oxidase inhibitor ( MAOI ) two week ( 14 day ) prior study participation two week ( 14 day ) end study participation . Subjects must normal clinically acceptable physical exam Electrocardiogram ( ECG ) interval ( PR , QRS , QT QTc ) 12lead ECG ( record 25 millimeters/second [ mm/s ] ) . Subjects must mean 5 minute rest sit systolic/diastolic office blood pressure ≤ 138/88 millimeter mercury ( mmHg ) . Subjects control diabetes prior entry must mean sit 5 minute rest systolic/diastolic office blood pressure ≤ 128/78 mmHg nondominated arm Females must urine serum pregnancy test ( Human Chorionic Gonadotropin ) negative Screening Day 1 Period 1 . Female subject childbearing potential must use medically acceptable birth control measure . Subjects must understand dose schedule . Subjects must able read write English . Subjects must significant medical condition , judgment Investigator , contraindication use phenylephrine HCl , might interfere study require treatment expect affect blood pressure . These may include hyperthyroidism , hypothyroidism , uncontrolled diabetes mellitus , coronary heart disease , ischemic heart disease , elevate intraocular pressure , prostatic hypertrophy . Subjects history clinically significant local systemic infectious disease within four week prior initial treatment administration . Subjects received investigational drug within 30 day prior study dose . Subjects , appear , know , current former drug addict alcoholic . Subjects positive hepatitis B surface antigen hepatitis C antibody . Subjects positive HIV antibody . Subjects clinically significant history food drug allergy . Subjects know allergy intolerance phenylephrine HCl . Females pregnant , nurse unwilling use/practice adequate contraception ( hormonal , Intrauterine Device , barrier method , etc. ) . Subjects take topical oral decongestant product within 7 day Visit 2 . Subjects take antihypertensive medication . Subjects take monoamine oxidase inhibitor . Subjects take tricyclic antidepressant ( e.g . amitriptyline , nortriptyline , imipramine ) Subjects take antithyroid medication ( e.g . propylthiouracil , methimazole , iodide ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>